Now showing items 1-9 of 9

    • Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. 

      Turner, NC; Kingston, B; Kilburn, LS; Kernaghan, S; Wardley, AM; Macpherson, IR; Baird, RD; Roylance, R; Stephens, P; Oikonomidou, O; Braybrooke, JP; Tuthill, M; Abraham, J; Winter, MC; Bye, H; Hubank, M; Gevensleben, H; Cutts, R; Snowdon, C; Rea, D; Cameron, D; Shaaban, A; Randle, K; Martin, S; Wilkinson, K; Moretti, L; Bliss, JM; Ring, A (2020-10)
      <h4>Background</h4>Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA ...
    • Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. 

      Izquierdo, E; Yuan, L; George, S; Hubank, M; Jones, C; Proszek, P; Shipley, J; Gatz, SA; Stinson, C; Moore, AS; Clifford, SC; Hicks, D; Lindsey, JC; Hill, RM; Jacques, TS; Chalker, J; Thway, K; O'Connor, S; Marshall, L; Moreno, L; Pearson, A; Chesler, L; Walker, BA; De Castro, DG (2017-12-06)
      The implementation of personalised medicine in childhood cancers has been limited by a lack of clinically validated multi-target sequencing approaches specific for paediatric solid tumours. In order to support innovative ...
    • Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. 

      Shern, JF; Selfe, J; Izquierdo, E; Patidar, R; Chou, H-C; Song, YK; Yohe, ME; Sindiri, S; Wei, J; Wen, X; Rudzinski, ER; Barkauskas, DA; Lo, T; Hall, D; Linardic, CM; Hughes, D; Jamal, S; Jenney, M; Chisholm, J; Brown, R; Jones, K; Hicks, B; Angelini, P; George, S; Chesler, L; Hubank, M; Kelsey, A; Gatz, SA; Skapek, SX; Hawkins, DS; Shipley, JM; Khan, J
      <h4>Purpose</h4>Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond ...
    • Genomic profile of advanced breast cancer in circulating tumour DNA. 

      Kingston, B; Cutts, RJ; Bye, H; Beaney, M; Walsh-Crestani, G; Hrebien, S; Swift, C; Kilburn, LS; Kernaghan, S; Moretti, L; Wilkinson, K; Wardley, AM; Macpherson, IR; Baird, RD; Roylance, R; Reis-Filho, JS; Hubank, M; Faull, I; Banks, KC; Lanman, RB; Garcia-Murillas, I; Bliss, JM; Ring, A; Turner, NC (2021-04-23)
      The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma circulating ...
    • Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. 

      Chopra, N; Tovey, H; Pearson, A; Cutts, R; Toms, C; Proszek, P; Hubank, M; Dowsett, M; Dodson, A; Daley, F; Kriplani, D; Gevensleben, H; Davies, HR; Degasperi, A; Roylance, R; Chan, S; Tutt, A; Skene, A; Evans, A; Bliss, JM; Nik-Zainal, S; Turner, NC (2020-05-29)
      Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO ...
    • Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. 

      Khan, KH; Cunningham, D; Werner, B; Vlachogiannis, G; Spiteri, I; Heide, T; Mateos, JF; Vatsiou, A; Lampis, A; Damavandi, MD; Lote, H; Huntingford, IS; Hedayat, S; Chau, I; Tunariu, N; Mentrasti, G; Trevisani, F; Rao, S; Anandappa, G; Watkins, D; Starling, N; Thomas, J; Peckitt, C; Khan, N; Rugge, M; Begum, R; Hezelova, B; Bryant, A; Jones, T; Proszek, P; Fassan, M; Hahne, JC; Hubank, M; Braconi, C; Sottoriva, A; Valeri, N (2018-10)
      Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection of patient progression. However, how to exploit the predictive power of cfDNA as a liquid biopsy in the clinic remains unclear. ...
    • A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. 

      George, SL; Izquierdo, E; Campbell, J; Koutroumanidou, E; Proszek, P; Jamal, S; Hughes, D; Yuan, L; Marshall, LV; Carceller, F; Chisholm, JC; Vaidya, S; Mandeville, H; Angelini, P; Wasti, A; Bexelius, T; Thway, K; Gatz, SA; Clarke, M; Al-Lazikani, B; Barone, G; Anderson, J; Tweddle, DA; Gonzalez, D; Walker, BA; Barton, J; Depani, S; Eze, J; Ahmed, SW; Moreno, L; Pearson, A; Shipley, J; Jones, C; Hargrave, D; Jacques, TS; Hubank, M; Chesler, L (2019-11)
      BACKGROUND:For children with cancer, the clinical integration of precision medicine to enable predictive biomarker-based therapeutic stratification is urgently needed. METHODS:We have developed a hybrid-capture next-generation ...
    • Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. 

      Pascual, J; Lim, JSJ; Macpherson, IR; Armstrong, AC; Ring, A; Okines, AFC; Cutts, RJ; Herrera-Abreu, MT; Garcia-Murillas, I; Pearson, A; Hrebien, S; Gevensleben, H; Proszek, PZ; Hubank, M; Hills, M; King, J; Parmar, M; Prout, T; Finneran, L; Malia, J; Swales, KE; Ruddle, R; Raynaud, FI; Turner, A; Hall, E; Yap, TA; Lopez, JS; Turner, NC (2020-09-21)
      Cyclin-dependent kinase 4/6 (CDK4/6) and PI3K inhibitors synergize in <i>PIK3CA</i>-mutant ER-positive HER2-negative breast cancer models. We conducted a phase Ib trial investigating the safety and efficacy of doublet ...
    • Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. 

      Mansukhani, S; Barber, LJ; Kleftogiannis, D; Moorcraft, SY; Davidson, M; Woolston, A; Proszek, PZ; Griffiths, B; Fenwick, K; Herman, B; Matthews, N; O'Leary, B; Hulkki, S; Gonzalez De Castro, D; Patel, A; Wotherspoon, A; Okachi, A; Rana, I; Begum, R; Davies, MN; Powles, T; von Loga, K; Hubank, M; Turner, N; Watkins, D; Chau, I; Cunningham, D; Lise, S; Starling, N; Gerlinger, M (2018-11)
      <h4>Background</h4>Circulating free DNA sequencing (cfDNA-Seq) can portray cancer genome landscapes, but highly sensitive and specific technologies are necessary to accurately detect mutations with often low variant ...